Immatics (IMTX) Stock Price, News & Analysis

Company Overview

Immatics N.V. is a biopharmaceutical company focused on developing T cell receptor (TCR)-based therapies for cancer. The company aims to identify cancer targets that are presented on the surface of tumor cells and develop treatments that enable T cells to recognize and attack those cells, including targets that may be difficult to address with conventional antibody-based medicines.

Immatics’ technology platforms support two primary approaches: TCR-engineered T-cell therapies, known as TCR-T, and TCR-based bispecific molecules designed to direct patients’ T cells toward tumor cells. Its pipeline has included investigational programs targeting cancer-associated antigens such as PRAME, with potential applications across solid tumors and other cancers. These programs remain subject to clinical development and regulatory review.

Founded in 2000, Immatics is headquartered in Tübingen, Germany, and operates internationally, serving the global biopharmaceutical market through its research, clinical-development and strategic collaboration activities. The company’s leadership includes Harpreet Singh, Ph.D., who serves as chief executive officer. Immatics’ American depositary shares trade on the Nasdaq Global Select Market under the symbol “IMTX.”

Key Stats

• Today's Range: $8.25 to $8.50
• 50-Day Range: $8.33 to $9.77
• 52-Week Range: $7.10 to $12.41
• Volume: 378,809 shs
• Average Volume: 600,668 shs
• Market Capitalization: $1.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.60
• Consensus Rating: Moderate Buy

Immatics Stock Analysis - MarketRank™

Immatics scored higher than 70% of companies evaluated by MarketBeat, and ranked 216th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immatics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Immatics has a consensus price target of $20.60, representing about 146.1% upside from its current price of $8.37.

Amount of Analyst Coverage

Immatics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immatics are expected to decrease in the coming year, from ($2.00) to ($2.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immatics is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immatics is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immatics has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.36% of the float of Immatics has been sold short.

Short Interest Ratio / Days to Cover

Immatics has a short interest ratio ("days to cover") of 8.27.

Change versus previous month

Short interest in Immatics has recently decreased by 8.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immatics does not currently pay a dividend.

Dividend Growth

Immatics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.64

News Sentiment

Immatics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Immatics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for IMTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Immatics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $7,499,991.00 in company stock, which represents 0.6555% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Immatics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,499,991.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/18/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMTX
• CIK: 1809196
• Web: www.immatics.com
• Phone: 4.97072E+12
• Fax: N/A
• Employees: 704
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Immatics: $20.60
• High Price Target: $25.00
• Low Price Target: $17.00
• Potential Upside/Downside: +146.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$222.26 million
• Net Margins: -495.71%
• Pretax Margin: -495.98%
• Return on Equity: -47.41%
• Return on Assets: -39.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.54
• Quick Ratio: 7.54

Sales & Book Value

• Annual Sales: $54.60 million
• Price / Sales: 20.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.09 per share
• Price / Book: 2.05

Miscellaneous

• Outstanding Shares: 136,690,000
• Free Float: N/A
• Market Cap: $1.14 billion
• Optionable: Optionable
• Beta: 1.33